The Triple-Agonist Revolution: Retatrutide and What Comes Next

It started with a hormone that vanished too fast

Glucagon-like peptide-1 (GLP-1) is a gut hormone the body releases after eating. It sharpens insulin release, blunts glucagon, slows gastric emptying and signals satiety to the brain. On paper it is an almost perfect metabolic switch. In practice, native GLP-1 has a half-life of only a minute or two — the enzyme DPP-4 dismantles it almost as fast as it appears. That single pharmacokinetic flaw is the reason the last fifteen years of incretin research happened at all: the biology was compelling, but the molecule itself was useless as a sustained intervention.

The entire arc that follows is a series of answers to one question — how do you keep this signal switched on, and can you widen what it switches?

Step one: make GLP-1 last

The first breakthrough was durability, not new biology. By re-engineering the peptide backbone to resist DPP-4 and adding a fatty-acid chain that binds albumin, researchers stretched GLP-1's half-life from minutes to about a week. Semaglutide is the landmark of this generation: a long-acting, once-weekly GLP-1 receptor agonist. In the STEP research programme it produced roughly 15% body-weight reduction — a figure no earlier agent had approached, and proof that a single incretin receptor, held on continuously, could move the needle in a way native GLP-1 never could.

Semaglutide reset expectations. But it also drew a line: activating one receptor, however cleanly, appeared to have a ceiling. To go further, the field had to add receptors.

Step two: add GIP and go dual

Glucose-dependent insulinotropic polypeptide (GIP) is GLP-1's sibling incretin. On its own it was long dismissed as therapeutically uninteresting, but paired with GLP-1 agonism something changed — the two signals appeared to complement each other, improving insulin handling and, importantly, tempering the nausea that limits how much GLP-1 signalling a subject tolerates. Tirzepatide was the first dual GIP/GLP-1 agonist to reach the clinic, and the numbers stepped up accordingly: around 22.5% body-weight reduction in the SURMOUNT-1 research programme.

The lesson of the dual agonists is the through-line of this whole story: adding a second, well-chosen receptor did not just add a little — it raised the achievable maximum. The ceiling moved. Our explainer on GLP-1 vs GIP vs glucagon agonists breaks down what each receptor actually contributes.

Step three: add glucagon and go triple

If GIP was the surprising addition, glucagon is the counter-intuitive one. Glucagon is best known as insulin's opposite — it raises blood sugar — so deliberately building it into a metabolic agent sounds backwards. The insight is that glucagon does something no incretin does: it increases energy expenditure. Where GLP-1 and GIP work primarily by reducing intake (appetite, satiety, gastric emptying), the glucagon arm attacks the other side of the balance sheet by nudging the body to burn more.

That "reduce intake and increase expenditure" logic is the whole rationale for triple agonism. Retatrutide (LY3437943) is the leading triple GIP/GLP-1/glucagon agonist, and its research results are the strongest reported in the class: approximately 24.2% body-weight reduction in the TRIUMPH-1 research programme — and notably, the curve had not clearly plateaued. Add a receptor, raise the ceiling; the pattern held a third time. For the full mechanism, see what Retatrutide is, and for how the molecule came to be, our history of Retatrutide.

Why adding a receptor keeps working

It is worth asking why the pattern repeats rather than treating it as luck. Each receptor engages a partly independent lever on energy balance: GLP-1 dominates central satiety and gastric emptying; GIP appears to improve tolerability and metabolic handling; glucagon adds thermogenic expenditure. Because the levers are not fully redundant, combining them tends to be additive rather than merely overlapping — and because tolerability improves with the right pairings, subjects can sustain more total signalling. More independent levers, better tolerated, equals a higher ceiling. That is the mechanistic reason the arc has not flattened yet.

What comes next

Retatrutide is the current frontier, not the end of the road. Several research directions are already in view:

• Glucagon-heavy duals for liver disease. Survodutide and Mazdutide are GLP-1/glucagon dual agonists being studied with a strong emphasis on the glucagon arm — of particular interest for MASH (metabolic dysfunction-associated steatohepatitis), where the liver-directed effects of glucagon signalling are a research focus in their own right.
• Amylin combinations. Cagrilintide is a long-acting amylin analogue — a different satiety pathway entirely. Paired with semaglutide as CagriSema, it represents a parallel strategy: instead of stacking incretin receptors, combine an incretin agonist with a wholly separate appetite hormone.
• Beyond three receptors. The obvious question the triple agonists raise is whether a fourth well-chosen target could move the ceiling again. That is speculative today, but the logic of the last decade suggests the field will try.

The bottom line

The story of incretin research is remarkably linear: a promising hormone that vanished too fast, made durable (Semaglutide), then broadened with a second receptor (Tirzepatide), then a third (Retatrutide) — each step raising the ceiling on effect size because each added a partly independent lever on energy balance. Retatrutide, the triple GIP/GLP-1/glucagon agonist, is where that arc currently points. The next chapters — glucagon-heavy agents for MASH, amylin combinations like CagriSema — are already being written. All of the above are investigational, research-only compounds; the interesting part, for researchers, is how cleanly the science has followed its own logic.